Why Teva Pharmaceuticals Has Significant Upside
Teva Pharmaceuticals | April 25, 2017
The strong fourth-quarter earnings report from Teva Pharmaceuticals (NYSE:TEVA) is but a distant memory. Despite reporting revenue growth of 33 percent and issuing non-GAAP earnings per share guidance of up to $5.30.